MoonLake Immunotherapeutics (MLTX)
39.74
-1.12
(-2.74%)
USD |
NASDAQ |
May 17, 16:00
39.74
0.00 (0.00%)
After-Hours: 20:00
MoonLake Immunotherapeutics Research and Development Expense (Quarterly): 13.01M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 13.01M |
| December 31, 2023 | 8.098M |
| September 30, 2023 | 7.585M |
| June 30, 2023 | 8.704M |
| March 31, 2023 | 7.415M |
| December 31, 2022 | 11.37M |
| Date | Value |
|---|---|
| September 30, 2022 | 9.024M |
| June 30, 2022 | 11.40M |
| March 31, 2022 | 10.45M |
| September 30, 2021 | 0.6695M |
| June 30, 2021 | 29.87M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.6695M
Minimum
Sep 2021
29.87M
Maximum
Jun 2021
10.69M
Average
9.024M
Median
Sep 2022
Research and Development Expense (Quarterly) Benchmarks
| Qiagen NV | 51.33M |
| LENZ Therapeutics Inc | 10.54M |
| AC Immune SA | 17.35M |
| CRISPR Therapeutics AG | 76.17M |
| Addex Therapeutics Ltd | 0.5126M |